Better Education on Glomerulonephritis: Recent Episodes
Annenberg Center for Health Sciences
Nephrology experts Jai Radhakrishnan, MD, and Dana Rizk, MD, delve into the complex disease of immunoglobulin A nephropathy (IgAN), addressing unmet treatment needs and novel frontiers of therapy. They discuss IgAN as a chronic disease, reviewing its pathophysiologic basis, morbidity and mortality including significant reductions in health-related quality of life, existing treatment options, and evolving new targeted therapies. The experts review treatment strategies, highlight case studies and share their experience improving long-term health outcomes.
- Phase 3 trials: targeted-release formulation-budesonide, atrasentan, sparsentan, iptacopan narsolimab
- Emerging therapies in Phase 2 trials
- Severity as a negative prognostic factor for IgAN
- Proteinuria reduction as a treatment goal
- Proteinuria reduction as a meaningful secondary endpoint for improved renal outcomes
- Proteinuria reduction and ESRD progression
- Clinical Presentation
- KDIGO Diagnosis
- KDIGO Prognosis
- Initial Assessment
- Scoring Tools: MEST-C score, International IgAN Prediction Tool